Search Results
Your search for ,wAS matches 27554 pages
Showing 18101 - 18150Jennifer Lycette, MD, Takes Pride in Delivering Cancer Care to Those Most in Need in Northwest Oregon
Born and reared in Anchorage, a city located in Southcentral Alaska, farther north than St. Petersburg, Russia, Jennifer Lycette, MD, grew up during the 1970s and 1980s. “We were fairly isolated from the lower 48. We didn’t have cable TV in Anchorage, and I remember my father would turn off the TV ...
New President of the Skin Cancer Foundation Emphasizes Public Education to Reduce Skin Cancer Incidence and Deaths
The statistics on the rising rates of skin cancer are alarming. According to the Skin Cancer Foundation, each year over 5.4 million cases of nonmelanoma skin cancer are treated in more than 3.3 million people, and an additional 76,380 people are diagnosed with the deadliest form of skin cancer,...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
Survivorship Symposium 2017: Almost Half of Partners and Caregivers of Young Breast Cancer Survivors Experience Long-Lasting Anxiety
While evidence is mounting on the physical and emotional challenges many cancer caregivers experience, few studies have addressed the experience of partners of young adults with cancer. Now, a new study evaluating the psychosocial concerns and mental health in the partners of young survivors of...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in follicular lymphoma. For full details of these study abstracts, visit http://www.bloodjournal.org/content/128/22....
AACR Receives $1.125 Million National Cancer Institute Grant to Continue Annual Clinical Trials Workshop
The American Association for Cancer Research (AACR) is pleased to announce that the National Cancer Institute (NCI) has awarded the organization a 5-year, $1.125 million grant to continue providing clinical fellow and junior faculty clinical researchers the opportunity to learn the essentials of...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat) and been asked questions like, ‘Where are you really from?’ or ‘How old...
ASCO’s State Affiliate Council: Helping Practices to Meet the Challenges Ahead
ASCO’s State Affiliate Council serves as an advisory group to ASCO’s Board of Directors on issues relating to its State/Regional Affiliates and their members, and serves as a vehicle for effective communications between the Board and domestic membership. The Council is made up of physician...
Highlights From the 2017 Gastrointestinal Cancers Symposium and Cancer Survivorship Symposium
The 2017 Gastrointestinal Cancers Symposium was held from January 19–21. Direct your patients to www.cancer.net/blog to read about the recent findings in esophageal and colorectal cancers. In addition, the Cancer Survivorship Symposium is being held from January 27–28. Visit the Cancer.Net blog to ...
Predicting Outcomes in Older Patients With Cancer
In the French ELCAPA14 study reported in the Journal of Clinical Oncology, Ferrat et al found that four frailty classifications performed well in predicting outcomes in a cohort of patients aged ≥ 70 years with various cancers. Study Details The study involved 763 in- or outpatients with...
Survivorship Symposium 2017: Physical and Psychological Factors Contribute to Decreased Physical Activity in 75% of Patients With Cancer
Although, in the past, patients with cancer were often counseled by their physicians to rest and reduce their physical activity, according to the American Cancer Society, emerging data are showing that exercise is not only safe and possible during cancer treatment, it can improve patients’...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time member and volunteer, has been elected to serve as President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to the ASCO...
Conquer Cancer Foundation Researcher Spotlight: Vamsidhar Velcheti, MD
What if more patients with lung cancer could benefit from immunotherapy? Although progress in this area of research is exciting, unfortunately, a vast majority of patients with thoracic malignancies do not respond to this pioneering form of treatment. Vamsidhar Velcheti, MD, Assistant Professor of ...
ASCO, AMP, and CAP Issue New Joint Guidelines to Standardize Interpretation and Reporting of Sequence Variants in Cancer
On December 16, a set of joint guidelines developed by ASCO, the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) on standardizing the interpretation and reporting of sequence variants in cancer was published online, ahead of the January print issue of The...
PARP Inhibitor Niraparib Yields ‘Unprecedented’ Results in Ovarian Cancer in Phase III Trial
The first phase III trial of an inhibitor of poly (ADP-ribose) polymerase (PARP) yielded unprecedented results in treating ovarian cancer. The trial was presented at the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, and electronically reported concurrently in The New England ...
Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial (ENGOT-OV16/NOVA) reported at the 2016 ESMO (European Society for Medical Oncology) Congress and in The New England Journal of Medicine by Mansoor R. Mirza, MD, of the Rigshospitalet–Copenhagen University Hospital, and colleagues, maintenance therapy with the PARP (poly...
Survivorship Symposium 2017: Younger Survivors of Thyroid Cancer Face Increased Risk of Hypertension, Heart Disease, and Osteoporosis
According to the American Cancer Society, in the United States, thyroid cancer is the most rapidly increasing cancer, tripling in the past 3 decades, and is commonly diagnosed at a younger age than most other adult cancers. A study by Blackburn et al examining whether survivors of thyroid cancer...
Diane M. Simeone, MD, to Lead New Pancreatic Cancer Center at NYU Langone
New York University (NYU) Langone Medical Center has announced that surgeon and scientist Diane M. Simeone, MD, will join its Perlmutter Cancer Center on March 1, 2017, to serve as Associate Director for Translational Research and to lead its newly established Pancreatic Cancer Center. Currently...
Understanding Cancer Epigenetics and Its Clinical Implications
The field of epigenetics emerged in the 1990s and has been described with somewhat variable meanings. In 2008, a meeting at the Cold Spring Harbor laboratory arrived at a definition of epigenetics by consensus: “A stably heritable phenotype resulting from changes in a chromosome without...
Paul Sondel, MD, PhD, Receives 2017 SITC Memorial Lectureship Award
Pediatric oncologist Paul Sondel, MD, PhD, of the University of Wisconsin Carbone Cancer Center, has been awarded a top prize in the field of cancer immunology. The Society for Immunotherapy of Cancer (SITC) announced that Dr. Sondel has received the group’s top award—the Richard V. Smalley, MD,...
Diamonds Are Forever, Tyrosine Kinase Inhibitors Are Not?
Sir Donald Munger: “You have been on holiday, I understand. Relaxing, I hope?” James Bond: “Oh, hardly relaxing, but most satisfying.” (Diamonds Are Forever) As tyrosine kinase inhibitors became the mainstay of therapy for patients with chronic myeloid leukemia (CML), our assumption has been that...
Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years
As reported in the Journal of Clinical Oncology by Gabriel Etienne, MD, PhD, of the Institut Bergonié, Bordeaux, and colleagues, long-term follow-up in the French Stop Imatinib (STIM1) study indicates that imatinib can be safely stopped in patients with chronic myeloid leukemia (CML) with...
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Nivolumab Improves Overall Survival in Recurrent Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Robert L. Ferris, MD, PhD, of the University of Pittsburgh Medical Center and Cancer Institute, and colleagues found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with...
Chi Van Dang, MD, PhD, Appointed Scientific Director of the Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research announced the appointment of Chi Van Dang, MD, PhD, as its Scientific Director. A hematologic oncologist and renowned researcher, Dr. Dang joins Ludwig from the University of Pennsylvania Perelman School of Medicine’s Abramson Cancer Center, which he has...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma
As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation therapy for glioblastoma.1 The endorsement was based on review ...
Moffitt Cancer Center Names Robert Wenham, MD, MS, FACOG, FACS, Gynecologic Oncology Program Chair
Moffitt Cancer Center has appointed Robert Wenham, MD, MS, FACOG, FACS, as the new Gynecologic Oncology Program Chair. Dr. Wenham has served as the Interim Chair over the past several months. He was recruited to Moffitt in 2004, after completing his fellowship in gynecologic oncology at the Duke...
Optimizing Access to Fertility Preservation Options
Ensuring that people with cancer understand how cancer treatment could affect their fertility and what options are available for preserving fertility were widely recognized as top priorities by attendees of the 2016 Oncofertility Conference in Chicago. As detailed at the conference, means of...
Antiretroviral Agent Makes Strong Showing in Refractory Multiple Myeloma
An antiretroviral drug that is used for human immunodeficiency virus (HIV) demonstrated strong activity when combined with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma in a small multicenter phase II study presented at the 2016 American Society of Hematology (ASH)...
Brentuximab Vedotin Plus Nivolumab Highly Active in Relapsed Classical Hodgkin Lymphoma
Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. The findings were presented at the 2016 American Society of Hematology (ASH) Annual Meeting &...
CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
Expert Point of View: Philip McCarthy, MD
The ASCO Post asked Philip McCarthy, MD, Professor of Oncology and Internal Medicine at Roswell Park Cancer, Buffalo, and Director of the Blood and Marrow Transplant Center there, to comment on these study findings. He first addressed the need to study earlier intervention for smoldering ...
High Response Rates to Triplet Therapy in Smoldering Myeloma
High-risk patients with smoldering multiple myeloma responded to a regimen of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone, in a multicenter phase II study led by Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston.1 “The high response rates among this patient...
Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD
Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral density test can help identify candidates for bone-modifying agents. “We look at women who are going on...
Ibandronate Fails to Improve Disease-Free Survival in Early Breast Cancer Patients—but With Favorable Trends
Addition of the oral bisphosphonate ibandronate to endocrine therapy did not significantly improve disease-free survival in patients with early breast cancer, according to the first results from the Dutch TEAM IIb trial presented at the 2016 San Antonio Breast Cancer Symposium.1 The results were...
Breast Cancer Experts Question New Recommendations for 21-Gene Recurrence Score Assay
At the 2016 San Antonio Breast Cancer Symposium, a group of breast cancer experts made a case for using the 21-gene Oncotype DX Breast Recurrence Score Assay in node-positive patients, despite ASCO’s latest recommendations to restrict it to node-negative estrogen receptor–positive patients. The...
Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....
Expert Point of View: Steven Vogl, MD
Presentation of the PERTAIN study data by lead author Grazia Arpino, MD, PhD, was met with high interest at the 2016 San Antonio Breast Cancer Symposium. Steven Vogl, MD, of the Bronx, New York, commented, “This is a very complicated study for me, but it seems that at least half your patients got...
Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer
In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herceptin) and an aromatase inhibitor in the first-line setting significantly improved progression-free ...
2017 GI Cancers Symposium: Less Than Half of Recommended Adults Screened for Lynch Syndrome
A team of researchers at Fox Chase Cancer Center found that, despite the recommendation of screening guidelines, less than half of adults younger than 50 years old who have colorectal cancer are being screened for Lynch syndrome, a genetic anomaly that increases the risk of colorectal and several...
2017 GI Cancers Symposium: Nivolumab Demonstrated Efficacy and Improved Survival in Patients With Previously Treated Advanced Gastric Cancer
Results of the ONO-4538-12 trial demonstrated that nivolumab (Opdivo) significantly reduced the risk of death by 37% (hazard ratio [HR] = 0.63; P < .0001) in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current ...
Risk Factors for Estrogen Receptor–Positive and –Negative Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Kerlikowske et al identified risk factors for estrogen receptor–positive and –negative breast cancer using data from the Breast Cancer Surveillance Consortium. The analysis included 1,279,443 women, aged 35 to 74...
Novel Antibody-Drug Conjugate Targets Triple-Negative Breast Cancer
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) produced high objective response rates, many of them quite durable, in a multicenter study of heavily pretreated patients with metastatic triple-negative breast cancer, presented at the 2016 San Antonio Breast Cancer Symposium.1 Trop-2 is ...
Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...
Osimertinib Significantly Improves Survival for Patients With Non–Small Cell Lung Cancer
For patients with epidermal growth factor receptor (EGFR) T790M–positive non–small cell lung cancer (NSCLC), osimertinib (Tagrisso) demonstrated clinically superior efficacy over pemetrexed (Alimta) plus a platinum agent, with a 70% reduction in the risk of disease progression, according to the...
What Precisely Is Precision Oncology—and Will It Work?
We know from chaos theory that even if you had a perfect model of the world, you’d need infinite precision in order to predict future events. —Nassim Nicholas Taleb The term “precision oncology” is used to describe diverse strategies in cancer medicine ranging from the use of targeted therapies...
Oncology Drug Approvals in 2016
In 2016, the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) approved a number of new molecular entities, indications, and tests. The most notable were drug approvals in disease areas such as non–small cell lung cancer, myeloma, head and neck cancer, and...
Precision Medicine Analysis of 203 Pediatric Brain Tumors May Advance Diagnosis and Treatment
Precision medicine has advanced to the point where it can now impact the care of a majority of children with brain tumors, a new study by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center suggests. In the largest clinical study to date of genetic abnormalities in...
Higher Intake of Grilled/Barbecued and Smoked Meat Linked to Reduced Survival After Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Parada et al found that higher intake of grilled/barbecued and smoked meat may be associated with poorer overall survival in breast cancer survivors. Grilled/barbecued and smoked meat, a source of polycyclic aromatic hydrocarbon...
Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1–2 N1–2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma....
